Takeda awards A$100,000 Australian medical research grants

29 Nov 2018

Takeda, Japan’s largest pharmaceutical company, has awarded individual grants of approximately A$100,000 to four Australian research programs as part of its COCKPI-T open innovation program.

The program is designed to support Australian research projects with the aim of advancing therapeutic targets and technologies in drug discovery. It funds early-stage research proposals related to therapeutic targets and technologies for drug discovery in neuroscience, oncology, gastroenterology and regenerative medicine.

The successful 2018 candidates are:

  • Dr Mayuresh Korgaonkar, Research Director, Westmead Institute for Medical Research and University of Sydney, for neuroscience
  • Associate Professor Trent Woodruff, School of Biomedical Sciences, University of Queensland, for neuro-immunology
  • Andrew Greenhill, Senior Lecturer, Federation University Australia, for gastroenterology
  • Professor Richard D’Andrea, University of South Australia; and Dr Nikki Verrills, University of Newcastle and Hunter Medical Research Institute, for oncology

As well as receiving individual grants, the candidates, who were selected from more than 60 applicants, are eligible for in-kind support from Takeda personnel.

‘Takeda is pleased to be able to support and encourage high-quality Australian research through investment in these early-stage programs at various universities,’ says James Jones, Managing Director of Takeda Australia in Biotech Dispatch.

‘The COCKPI-T Australia 2018 program attracted many excellent applications across the therapeutic areas that Takeda focuses on, reaffirming Australia’s strong reputation in innovative academic and clinical research.

‘We congratulate the successful applicants and look forward to their contribution in understanding complex disease areas.’

Headquartered in Tokyo, Japan, Takeda Pharmaceuticals was founded in 1781. Co-Create Knowledge for Pharma Innovation with Takeda (COCKPI-T) was launched in Japan in 2015 and introduced to Australia in 2018 – the first overseas market to receive it. COCKPI-T in Australia is operated by the company’s Shonan Research Centre in Japan in collaboration with Takeda Australia.